Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ACVR1B | P36896 | 8/20 | 0.54 |
| ▸ | ACVRL1 | P37023 | 7/20 | 0.54 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2211327 | 0.88 | NUDT1 (0.56) | TGFBR1CYP3A4ACVR1BACVRL1NUDT1 | |
| SCHEMBL2493823 | 0.83 | TGFBR1 (0.60) | TGFBR1ACVR1BACVRL1BMPR1AACVR1 | |
| SCHEMBL12190439 | 0.83 | TGFBR1 (0.60) | TGFBR1ACVR1BACVRL1BMPR1AACVR1 | |
| SCHEMBL2492437 | 0.82 | TGFBR1 (0.48) | TGFBR1CYP3A4ACVR1BACVRL1NUDT1 | |
| SCHEMBL12426207 | 0.80 | TGFBR1 (0.57) | TGFBR1CYP3A4ACVR1BACVRL1PIM1 | |
| SCHEMBL2206244 | 0.80 | TGFBR1 (0.57) | TGFBR1CYP3A4ACVR1BACVRL1PIM1 | |
| SCHEMBL8344359 | 0.80 | TGFBR1 (0.59) | TGFBR1CYP3A4ACVR1BACVRL1NUDT1 | |
| SCHEMBL8344363 | 0.79 | TGFBR1 (0.63) | TGFBR1CYP3A4ACVR1BACVRL1NUDT1 | |
| SCHEMBL13649377 | 0.79 | TGFBR1 (0.57) | TGFBR1CYP3A4ACVR1BACVRL1NUDT1 | |
| SCHEMBL3827835 | 0.79 | TGFBR1 (0.59) | TGFBR1CYP3A4ACVR1BACVRL1NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | claimed |
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | disclosed |
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | disclosed |
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | disclosed |
| EP-1869037-B1 | HETEROBICYLIC INHIBITORS OF HVC | TIBOTEC PHARM LTD (IE) | 2011-07-27 | — | — | EP | disclosed |
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | TIBOTEC BVBA (BE) | 2008-07-31 | — | — | US | disclosed |
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | TIBOTEC BVBA (BE) | 2008-07-31 | — | — | US | disclosed |
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | TIBOTEC BVBA (BE) | 2008-07-31 | — | — | US | disclosed |
| US-20070066632-A1 | Fused bicyclic inhibitors of TGFbeta | SCIOS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066632-A1 | Fused bicyclic inhibitors of TGFbeta | SCIOS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | HAVCR2, GTF3C4, CUL4A | TGFBR1 3950/4885CYP3A4 104/4885ACVR1B 2630/4885 |
| US-20070066632-A1 | Fused bicyclic inhibitors of TGFbeta | TGFBR1, TGFB1, SMAD2 | TGFBR1 1/4885CYP3A4 2204/4885ACVR1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.